查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403407

2030 年小分子免疫调节药物市场预测：按产品、应用、最终用户和地区进行的全球分析

Small Molecule Immunomodulators Market Forecasts to 2030 - Global Analysis By Product, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC的数据，2023年全球小分子免疫调节剂市场规模为1,690.6亿美元，预计到2030年将达到2,935.2亿美元，预测期内复合年增长率为8.2%。

小分子免疫调节剂是可以调节免疫系统的小分子化合物。这些化合物在调节免疫反应、根据需要增强或抑制免疫反应方面发挥重要作用。小分子免疫调节药物在治疗多种疾病（包括自体免疫疾病、发炎疾病和某些癌症）方面具有微调免疫系统活性并提高疗效的潜力，使其成为免疫疗法的有吸引力的选择。在该领域研究过。

根据美国国家多发性硬化症协会 2020 年 9 月发布的报告，全球有 280 万人患有多发性硬化症，光是美国居住超过 100 万人。

免疫疾病增加

免疫疾病的流行已成为小分子免疫调节药物的重要驱动力。随着自体免疫疾病和其他免疫疾病变得越来越普遍，对创新治疗方法的需求不断增长。小分子免疫调节剂旨在在分子层面上调节免疫反应，并因其控制这些疾病的潜力而受到重视。免疫疾病盛行率的上升是研究、开发和市场开拓的驱动力。

副作用和安全问题

小分子免疫调节剂可能与胃肠道失调、皮肤反应和免疫抑制等副作用有关。安全性问题包括可能对免疫功能的长期影响和机会性感染疾病的风险。此外，药物交互作用和反应的个体差异也带来了挑战。此外，这些免疫调节剂的长期影响仍在接受审查，对潜在突发事件的担忧进一步阻碍了市场需求。

药物开发的进展

标靶治疗、个人化医疗和新型小分子化合物等创新在调节免疫系统方面显示出有希望的结果。这些进步不仅提高了治疗效果，还有助于最大限度地减少副作用。免疫调节药物开发的进展正在创造有利的市场开拓环境，并为透过有针对性的有效干预措施解决各种疾病和病症提供新途径。

学名药竞争

由于主要免疫调节剂的专利到期，小分子免疫调节剂正面临学名药的激烈竞争。当专利到期时，学名药公司可以进入市场并提供更实惠的品牌药替代品。这种日益激烈的竞争为患者提供了具有成本效益的选择。製药公司之间的竞争加剧可能会降低创新製药公司的报酬率并阻碍市场扩张。

COVID-19 的影响

COVID-19的爆发对小分子免疫调节药物市场产生了重大影响。人们越来越关注增强免疫反应和治疗发炎疾病，这增加了对免疫调节剂的需求。然而，药品供应链的中断、临床试验的延误和经济的不确定性正在影响市场的成长。这次疫情凸显了免疫调节药物研发的重要性，但製造和分销方面的挑战限制了市场的扩张。总体而言，市场正在经历持续的全球健康危机所带来的机会和挑战的混合影响。

在预测期内，心臟手术领域预计将是最大的。

由于其准确性和有效性，心臟手术领域预计将出现良好的增长。小分子免疫调节剂在心血管手术过程中调节免疫反应、减轻发炎反应、优化身体对手术的耐受性方面发挥重要作用。这可以最大限度地减少术后併发症并改善患者的整体治疗效果。这种免疫调节剂的精确性和标靶性使其成为心血管手术领域有价值的辅助手段。

预计医院和诊所产业在预测期内将经历最高的复合年增长率。

医院和诊所预计在预测期内复合年增长率最高。在医院和诊所，小分子免疫调节剂市场透过调节免疫反应在解决各种医疗状况方面发挥着至关重要的作用。这些药物给药治疗自体免疫疾病、癌症和发炎疾病。这些药物有助于改善患者的预后，同时最大限度地减少与副作用相关的风险。其有效性和安全性正在推动该领域的发展。

比最大的地区

由于免疫疾病患者数量不断增加，预计亚太地区在预测期内将占据最大的市场占有率。人们对这些疾病的认识不断提高，医疗保健投资不断增加，正在推动市场扩张。此外，该地区老年人口的增长和生活方式的改变也导致自体自体免疫疾病的迅速增加。随着製药公司专注于创新免疫调节药物的开发和商业化，面对日益严峻的免疫挑战，迫切需要有效的治疗方法，亚太市场有望大幅成长。

复合年增长率最高的地区：

由于门诊外科手术的采用率增加以及对具有成本效益的医疗保健服务的重视，预计北美在预测期内将呈现最高的复合年增长率。自体自体免疫疾病的日益普及和人口高龄化正在推动对先进免疫调节疗法的需求。该地区拥有发达的医疗基础设施，持续的研究倡议正在促进市场扩张。主要企业正在投资开发新药，加强市场竞争形势。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球小分子免疫调节药物市场：副产品

  • 免疫抑制剂
    • Calcineurin抑制剂
    • 糖皮质素
    • mTOR抑制剂
  • 活化
    • 白细胞介素
    • 干扰素
  • 1-磷酸鞘氨醇 (S1P) 受体调节剂
  • Janus 激酶 (JAK) 抑制剂
  • 其他产品

第六章全球小分子免疫调节药物市场：依应用分类

  • 胸部
  • 眼科
  • 大肠直肠
  • 心血管手术
  • 神经外科
  • 整形外科
  • 妇科
  • 其他用途

第七章全球小分子免疫调节药物市场：依最终用户分类

  • 医院和诊所
  • 製药和生物技术公司
  • 研究和学术机构
  • 门诊手术中心
  • 居家照护环境
  • 其他最终用户

第八章全球小分子免疫调节药物市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司简介

  • Boston Scientific Corporation
  • Medline Industries
  • Molnlycke Health Care
  • Cardinal Health Inc
  • Owens & Minor, Inc.
  • B. Braun Melsungen AG
  • Teleflex Incorporated
  • Smith & Nephew Plc
  • Thermo Fisher Scientific Inc.
  • Halyard Health Inc
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Limited
  • Novartis AG
  • Odyssey Therapeutics Inc
Product Code: SMRC24632

According to Stratistics MRC, the Global Small Molecule Immunomodulators Market is accounted for $169.06 billion in 2023 and is expected to reach $293.52 billion by 2030 growing at a CAGR of 8.2% during the forecast period. Small molecule immunomodulators are compounds with low molecular weight that can regulate the immune system. These compounds play a crucial role in modulating immune responses, either enhancing or suppressing them as needed. Small molecule immunomodulators are extensively studied in the field of immunotherapy for their potential in treating various diseases, including autoimmune disorders, inflammatory conditions, and certain cancers, by fine-tuning the immune system's activity for therapeutic benefits.

According to a report published by the National Multiple Sclerosis Society in September 2020, there are 2.8 million people worldwide who have multiple sclerosis, and more than 1 million reside in the United States alone.

Market Dynamics:

Driver:

Rising incidence of immunological disorders

The escalating prevalence of immunological disorders is a key catalyst of the small molecule immunomodulators. As autoimmune diseases and other immunological disorders become more widespread, there is an increasing demand for innovative therapeutic solutions. Small molecule immunomodulators, designed to modulate the immune response at a molecular level, are gaining prominence for their potential in managing these conditions. This rising incidence of immunological disorders is thereby driving research, development, and market expansion.

Restraint:

Side effects and safety concerns

The small molecule immunomodulators may entail side effects such as gastrointestinal issues, skin reactions, and immune suppression. Safety concerns include potential long-term impacts on immune function and the risk of opportunistic infections. Additionally, drug interactions and individual variability in response pose challenges. Moreover, the long-term effects of these immunomodulators remain under scrutiny, raising concerns about potential unforeseen consequences which further hinder the market demand.

Opportunity:

Advancements in drug development

Innovations such as targeted therapies, personalized medicine, and novel small molecule compounds have shown promising results in modulating the immune system. These advancements not only enhance treatment efficacy but also contribute to minimizing adverse effects. The evolving landscape of drug development in immunomodulation creates a favourable environment for market growth, offering new avenues for addressing various diseases and disorders through precise and effective interventions.

Threat:

Generic competition

The small molecule immunomodulators witnesses robust generic competition due to the expiration of patents for key immunomodulatory drugs. As patents expire, generic pharmaceutical companies can enter the market, offering more affordable alternatives to the original branded drugs. This increased competition promotes cost-effective options for patients. This intensified competition among pharmaceutical companies, potentially leads to reduced profit margins for innovator companies thereby hampering the market expansion.

COVID-19 Impact

The COVID-19 pandemic has significantly impacted the small molecule immunomodulators Market. The increased focus on enhancing immune responses and treating inflammatory conditions has driven demand for immunomodulators. However, disruptions in the pharmaceutical supply chain, delayed clinical trials, and economic uncertainties have affected market growth. The pandemic has underscored the importance of research and development in immunomodulatory drugs, but challenges in manufacturing and distribution have tempered market expansion. Overall, the market has experienced a mixed impact with both opportunities and challenges arising from the ongoing global health crisis.

The cardiac surgery segment is expected to be the largest during the forecast period

The cardiac surgery segment is estimated to have a lucrative growth, due to its accuracy and efficacy. Small molecule immunomodulators play a crucial role in modulating the immune response during cardiac surgery, mitigating inflammatory reactions and optimizing the body's tolerance to the procedure. It minimizes postoperative complications and enhances overall patient outcomes. The precision and targeted nature of these immunomodulators makes them valuable adjuncts in the field of cardiac surgery.

The hospitals & clinics segment is expected to have the highest CAGR during the forecast period

The hospitals & clinics segment is anticipated to witness the highest CAGR growth during the forecast period. In hospitals and clinics, the Small Molecule Immunomodulators market plays a pivotal role in addressing diverse medical conditions by modulating immune responses. These pharmaceuticals are administered to manage autoimmune disorders, cancer, and inflammatory diseases. They contribute positive patient outcomes while minimizing risks associated with adverse reactions. Its efficacy and safety factors boost the segment growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to escalating cases of immunological disorders. The rising awareness of these conditions, coupled with increasing healthcare investments, is fostering market expansion. Moreover, the region's growing geriatric population and changing lifestyles contribute to the surge in autoimmune diseases. As pharmaceutical companies focus on developing and commercializing innovative immunomodulatory drugs, the Asia-Pacific market is poised for significant advancement, driven by the pressing need for effective treatments in the face of rising immunological challenges.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the increased adoption of outpatient surgical procedures and the growing emphasis on cost-effective healthcare services. Increased prevalence of autoimmune diseases and a rising aging population are driving demand for advanced immunomodulatory therapies. The region's well-established healthcare infrastructure and ongoing research initiatives contribute to market expansion. Key players are investing in novel drug development, bolstering the market's competitive landscape.

Key players in the market:

Some of the key players profiled in the Small Molecule Immunomodulators Market include Boston Scientific Corporation, Medline Industries, Molnlycke Health Care, Cardinal Health Inc, Owens & Minor, Inc., B. Braun Melsungen AG, Teleflex Incorporated, Smith & Nephew Plc, Thermo Fisher Scientific Inc., Halyard Health Inc, Eli Lilly and Company, Teva Pharmaceutical Industries Limited, Novartis AG and Odyssey Therapeutics Inc.

Key Developments:

In December 2022, Medline Industries, as part of the European Commission's rescEU program, donated 59 pallets containing 14 tons of medical supplies to Ukraine. The contribution included essential items like delivery kits, oxygen therapy equipment, scrub suits, and scalpels & sutures, aiding healthcare efforts in the country.

In October 2022, Odyssey Therapeutics Inc., a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, announced a $168 million Series B financing. The proceeds will enable Odyssey to advance its portfolio of precision immunomodulators and oncology medicines in support of its mission of developing innovative medicines to treat serious human diseases.

Products Covered:

  • Immunosuppressants
  • Immunostimulants
  • Sphingosine-1-Phosphate (S1P) Receptor Modulators
  • Janus Kinase (JAK) Inhibitors
  • Other Products

Applications Covered:

  • Thoracic
  • Ophthalmology
  • Colorectal
  • Cardiac Surgery
  • Neurosurgery
  • Orthopedic
  • Gynecology
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Research & Academic Institutes
  • Ambulatory Surgical Centers
  • Homecare Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Small Molecule Immunomodulators Market, By Product

  • 5.1 Introduction
  • 5.2 Immunosuppressants
    • 5.2.1 Calcineurin Inhibitors
    • 5.2.2 Glucocorticoids
    • 5.2.3 mTOR Inhibitors
  • 5.3 Immunostimulants
    • 5.3.1 Interleukins
    • 5.3.2 Interferons
  • 5.4 Sphingosine-1-Phosphate (S1P) Receptor Modulators
  • 5.5 Janus Kinase (JAK) Inhibitors
  • 5.6 Other Products

6 Global Small Molecule Immunomodulators Market, By Application

  • 6.1 Introduction
  • 6.2 Thoracic
  • 6.3 Ophthalmology
  • 6.4 Colorectal
  • 6.5 Cardiac Surgery
  • 6.6 Neurosurgery
  • 6.7 Orthopedic
  • 6.8 Gynecology
  • 6.9 Other Applications

7 Global Small Molecule Immunomodulators Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals & Clinics
  • 7.3 Pharmaceutical & Biotechnology Companies
  • 7.4 Research & Academic Institutes
  • 7.5 Ambulatory Surgical Centers
  • 7.6 Homecare Settings
  • 7.7 Other End Users

8 Global Small Molecule Immunomodulators Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Boston Scientific Corporation
  • 10.2 Medline Industries
  • 10.3 Molnlycke Health Care
  • 10.4 Cardinal Health Inc
  • 10.5 Owens & Minor, Inc.
  • 10.6 B. Braun Melsungen AG
  • 10.7 Teleflex Incorporated
  • 10.8 Smith & Nephew Plc
  • 10.9 Thermo Fisher Scientific Inc.
  • 10.10 Halyard Health Inc
  • 10.11 Eli Lilly and Company
  • 10.12 Teva Pharmaceutical Industries Limited
  • 10.13 Novartis AG
  • 10.14 Odyssey Therapeutics Inc

List of Tables

  • Table 1 Global Small Molecule Immunomodulators Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Small Molecule Immunomodulators Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Small Molecule Immunomodulators Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 4 Global Small Molecule Immunomodulators Market Outlook, By Calcineurin Inhibitors (2021-2030) ($MN)
  • Table 5 Global Small Molecule Immunomodulators Market Outlook, By Glucocorticoids (2021-2030) ($MN)
  • Table 6 Global Small Molecule Immunomodulators Market Outlook, By mTOR Inhibitors (2021-2030) ($MN)
  • Table 7 Global Small Molecule Immunomodulators Market Outlook, By Immunostimulants (2021-2030) ($MN)
  • Table 8 Global Small Molecule Immunomodulators Market Outlook, By Interleukins (2021-2030) ($MN)
  • Table 9 Global Small Molecule Immunomodulators Market Outlook, By Interferons (2021-2030) ($MN)
  • Table 10 Global Small Molecule Immunomodulators Market Outlook, By Sphingosine-1-Phosphate (S1P) Receptor Modulators (2021-2030) ($MN)
  • Table 11 Global Small Molecule Immunomodulators Market Outlook, By Janus Kinase (JAK) Inhibitors (2021-2030) ($MN)
  • Table 12 Global Small Molecule Immunomodulators Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 13 Global Small Molecule Immunomodulators Market Outlook, By Application (2021-2030) ($MN)
  • Table 14 Global Small Molecule Immunomodulators Market Outlook, By Thoracic (2021-2030) ($MN)
  • Table 15 Global Small Molecule Immunomodulators Market Outlook, By Ophthalmology (2021-2030) ($MN)
  • Table 16 Global Small Molecule Immunomodulators Market Outlook, By Colorectal (2021-2030) ($MN)
  • Table 17 Global Small Molecule Immunomodulators Market Outlook, By Cardiac Surgery (2021-2030) ($MN)
  • Table 18 Global Small Molecule Immunomodulators Market Outlook, By Neurosurgery (2021-2030) ($MN)
  • Table 19 Global Small Molecule Immunomodulators Market Outlook, By Orthopedic (2021-2030) ($MN)
  • Table 20 Global Small Molecule Immunomodulators Market Outlook, By Gynecology (2021-2030) ($MN)
  • Table 21 Global Small Molecule Immunomodulators Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 22 Global Small Molecule Immunomodulators Market Outlook, By End User (2021-2030) ($MN)
  • Table 23 Global Small Molecule Immunomodulators Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 24 Global Small Molecule Immunomodulators Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 25 Global Small Molecule Immunomodulators Market Outlook, By Research & Academic Institutes (2021-2030) ($MN)
  • Table 26 Global Small Molecule Immunomodulators Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 27 Global Small Molecule Immunomodulators Market Outlook, By Homecare Settings (2021-2030) ($MN)
  • Table 28 Global Small Molecule Immunomodulators Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.